Atracurium Besylate minial dose

PreclinicalSmall molecule

Atracurium Besylate minial dose is one of 14 small molecule programs targeting General Anesthesia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

General AnesthesiaRecruiting

General AnesthesiaPreclinical

Recruiting

Competition

Competitive Landscape

19 competitors in General Anesthesia

#DrugCompanyPhaseTrials

Anerem

AAcacia Pharma Ltd

Approved

7 2

Esmeron

Merck & Co.

Phase 3

3 3

Cypsedo

HHaisco-USA Pharmaceuticals, Inc.

Approved

1 4

Tegoprazan

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

1 5

Amidate

Pfizer

Phase 1

2 6

Robinul

Jazz Pharmaceuticals

Preclinical

1 7

Carbocaine

Pfizer

Preclinical

1 8

Ephedrine Sulfate

DDr. Reddys Laboratories, SA

Preclinical

2 9

Dexmedetomidine Hydrochloride

Pfizer

Preclinical

2 10

Opioid

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

General Anesthesia1 trial

Small Doses Muscle Relaxant in General Anesthesia

Recruiting·MMansoura University·N/A·NCT04344262·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Atracurium Besylate minial dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Atracurium Besylate minial dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Atracurium Besylate minial dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mansoura University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMansoura University

Atracurium Besylate minial dose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

General Anesthesia1 trial

References

Drug Info

Quick Facts

Related News